XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Gastric Cancer Clinical Trial

— EXPLORING  

Official title:

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494060
• Other study ID #: 2022-SR-342
• Status: Recruiting
• Phase: Phase 2
• Start date: March 16, 2022
• Est. completion date: February 2027

Study information

• Verified date: November 2023
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Yongqian Shu, PhD
• Phone: 0086-025-68306428
• Email: shuyongqian[@]csco.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks/cycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma.

Description:

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks/cycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma. The study includes a screening (up to 28 days), treatment (disease recurrence, unacceptable toxicity, or subject withdrawal of consent with a maximum 12 month), safety follow-up (up to 30 days following last study drug treatment), and survival follow-up phase.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: February 2027
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects aged =18 and =75 years old, male or female.

• ECOG performance status score 0-1.

• Histologically or cytologically confirmed GC or GEJ carcinoma, had been treated with Radical resection (D2, R0 or R1) of gastric cancer.

• Pathological stage:III (8th AJCC TNM).

• Estimated lifetime is greater than 6 months.

• The main organs are functioning well, and the blood test results within 14 days before enrollment should meet the following requirements:

1. Routine blood test:

1. Hemoglobin (HB) =90 g/L.

2. Neutrophil count (ANC) =1.5×109/L.

3. Platelet count (PLT) =100×109/L.

2. Biochemical test:

1. Total bilirubin=1.5×ULN (upper limit of normal).

2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5×ULN; if there is liver metastasis, ALT and AST = 5×ULN.

3. Serum creatinine (Cr) =1.5 ULN or creatinine clearance =60mL/min.

• No obvious clinical symptoms of heart disease.

• Must have disease-free status documented by complete physical examination and imaging studies with no evidence of recurrent, residual, or metastatic disease on standard imaging (chest, abdomen, and pelvis captured by CT chest and CT or MRI of abdomen and pelvis) per investigator assessment within 28 days prior to enrollment.

• Females of childbearing potential must have a negative urine or serum pregnancy test within 7 days of randomization and must be willing to use a highly effective method of birth control (Appendix 9) for the duration of the study, and = 120 days after the last dose of penpulimab and 180 days after the last dose of chemotherapy.

• Volunteer to participate in this study and sign an informed consent form.

• Considering that NGS analysis may take up to 10 working days, patients could receive 1 cycle of XELOX chemotherapy after ctDNA sampling.

Exclusion Criteria:

• Participation in other drug clinical trials within four weeks.

• Multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction.

• History of bleeding, any bleeding event with a severity grade of 3 or higher per CTCAE 5.0 within 4 weeks before screening.

• Patients with known central nervous system metastasis or history of central nervous system metastasis prior to screening. For patients with clinically suspected central nervous system metastases, CT or MRI must be performed within 28 days before enrollment to rule out central nervous system metastases.

• Patients with hypertension and uncontrolled by antihypertensive drugs alone (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); Patients with a history of unstable angina pectoris; Patients newly diagnosed as angina pectoris within 3 months before screening or myocardial infarction events within 6 months before screening; Arrhythmias (including QTcF = 450 ms in men, = 470 ms in women requiring long-term use of antiarrhythmic drugs and New York Heart Association Class = II cardiac insufficiency;There are many factors that affect oral drug absorption (such as inability to swallow, nausea and vomiting, upper gastrointestinal obstruction, abnormal physiological function, malabsorption syndrome, etc.), which may affect anlotinib hydrochloride absorbers.

• Long-term unhealed wound or unhealed fracture.

• Imaging findings show that the tumor has invaded around important blood vessels or the patient's tumor has a very high possibility of invading important blood vessels during treatment and causing fatal massive hemorrhage as judged by the investigator.

• Patients with abnormal coagulation function and bleeding tendency (the following criteria must be met within 14 days before randomization: INR is within normal range without anticoagulants or has no clinically significant abnormality); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues; patients with prothrombin time international normalized ratio (INR) = 1.5 are allowed to take low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (the daily dose does not exceed 100 mg) for preventive purposes.

• Arteriovenous thrombotic events occurred within 6 months before screening, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except venous thrombosis caused by previous chemotherapy that has been judged by the investigator to have recovered) and pulmonary embolism.

• Urine routine showed urine protein and 24 h urine protein was confirmed to be > 1.0g.

• Previous use of immune targeted therapy drugs.

• History of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.

• Patients with infectious pneumonia, pneumonitis, interstitial pneumonia and other conditions requiring corticosteroids.

• History of severe chronic autoimmune diseases, such as systemic lupus erythematosus; history of inflammatory bowel disease such as ulcerative enteritis, Crohn's disease, irritable bowel syndrome and other chronic diarrheal diseases; history of sarcoidosis or tuberculosis; history of active hepatitis B, C and HIV infection; well-controlled non-serious immune diseases, such as dermatitis, arthritis, psoriasis, etc. Hepatitis B virus < 1000 copies/ml can be detected.

• Patients with hypersensitivity to human or murine monoclonal antibodies.

• Patients with a history of psychotropic substance abuse and unable to quit or with mental disorders.

• Pleural or peritoneal effusion with clinical symptoms requiring clinical intervention.

• Patients who do not follow the doctor's advice, do not take medicine as required, or have insufficient data that can affect the efficacy judgment or safety judgment.

• Patients with concomitant diseases that, in the judgment of the investigator, seriously jeopardize the patient's safety or affect the patient's completion of the study.

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma
• Digestive System Diseases
• Digestive System Neoplasms
• Gastric Cancer
• Gastroesophageal-junction Cancer
• Gastrointestinal Diseases
• Gastrointestinal Neoplasms
• Stomach Cancer
• Stomach Neoplasms

Intervention

Drug:
• Anlotinib hydrochloride capsule
Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21);
• Penpulimab Injection
Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
• XELOX
Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

Locations

Country	Name	City	State
China	Jiangsu Province Hospital	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall survival (OS)	OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.	up to 4 years
Other	Toxicity by CTCAE v5.0 criteria	oxicity and safety analysis will occur in patients who received at least one full or partial dose of study treatment. Adverse events will be graded per NCI CTCAE v.5.0.	up to 4 years
Primary	Disease Free Survival (DFS)	From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence).	up to 2 years
Secondary	Disease Free Survival (DFS) rate at 2 years	From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence), assessed at 2 years.	2 years
Secondary	Disease Free Survival (DFS) rate at 3 years	From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence), assessed at 3 years.	3 years